Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection

NCT03198507 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT03198507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03198507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 3
Overall status
Completed
Start date
June 18, 2017
Completion date
December 13, 2018
Enrollment
455 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

dyspepsia, helicobacter pylori infection